Background
Brian Rifkin
The Ondansetron Ballet: Torsades de Pointes

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

The Ondansetron Ballet: Torsades de Pointes
Background
Cristina Adriana Popa
Re”FINE”ing the role of non steroidal MRAs in ...

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Background
Cristina Adriana Popa
Playing It Safe: Can Felzartamab Fill the Gap ...

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
Background
Jade Teakell
The pressure is on! Unravelling the ESPRIT of ...

This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.

The pressure is on! Unravelling the ESPRIT of Intensive vs Standard BP Control
Background
joel topf
Summer Book Club 2024. The Covenant of Water

The NephJC Summer Book Club returns! We turn to fiction this time, 'The Covenant of Water', from Abraham Verghese.

Summer Book Club 2024. The Covenant of Water

roxadustat

The Dual Dustat Visual abstracts

UPDATE:

On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.

The Incident dialysis visual abstract has been updated to reflect this change.

At their first attempt, the NSMC interns Alicja Rosolowska and Keia Sanderson have created beautiful visual abstract


The Roxadustat Chronicles: A Two-Article NephJC

The Roxadustat Chronicles: A Two-Article NephJC

The HIF inhibitor trials were announced almost a year and half ago at KidneyWk 2019. We are finally seeing the trials get published. Here are the first two, a sub-group analysis of three dialysis studies focused on incident dialysis patients and a placebo controlled pre-dialysis study.